- Видео 184
- Просмотров 768 719
COR2ED The Heart of Medical Education
Швейцария
Добавлен 4 дек 2021
COR2ED develops high-quality Independent Medical Education programmes to help healthcare professionals improve the health of patients globally.
Highlights: BRAF-mutated CRC: testing to treatment
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), the testing strategies and available treatments for these patients.
They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.
Several key trials are discussed, including the BEACON trial, which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF-mutated CRC.
The discussion also ...
They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.
Several key trials are discussed, including the BEACON trial, which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF-mutated CRC.
The discussion also ...
Просмотров: 38
Видео
BRAF-mutated CRC: testing to treatment
Просмотров 269 часов назад
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), the testing strategies and available treatments for these patients. They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF muta...
The emerging role of artificial intelligence in precision oncology
Просмотров 911День назад
Do you want to know more about the clinical application of Artificial Intelligence (AI) in pathology and in precision oncology now and in the future? In this clinical topic video, molecular pathologist Prof. Albrecht Stenzinger provides expert insight into how AI is starting to shape the pathology landscape, sharing his views on: - The requirements to successfully implement AI in precision onco...
Precision oncology in prostate cancer: tips for optimal genomic testing
Просмотров 1,8 тыс.Месяц назад
Have you ever wondered if you're getting the most out of genomic testing for prostate cancer? In this animated video, GU cancer genomics expert Dr Alexander Wyatt shares the guideline recommendations and best tips for precision oncology in prostate cancer. Multi-gene germline and somatic testing is required for the identification of gene alterations in advanced prostate cancer. Both tissue and ...
Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape
Просмотров 135Месяц назад
In this 3-part podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER /HER2- advanced or metastatic breast cancer. In this episode the experts explore the efficacy and safety profiles of oral SERDs and their place in the treatment landscape, and discuss how to optimise treatment selection and make appropriate sequencing decisions. Prefer to listen on the...
Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond
Просмотров 99Месяц назад
In this 3-part podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER /HER2- advanced or metastatic breast cancer. In this episode the experts deep-dive into two patient case studies of ER /HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusti...
Episode 3: Oral SERDS in ER+ breast cancer: rare cases & treatment challenges
Просмотров 142Месяц назад
In this 3-part podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER /HER2- advanced or metastatic breast cancer. In this final episode of this podcast the experts discuss the next two patient case studies of ER /HER2- metastatic breast cancer, each presenting unique and rare situations that shed a light on the challenges confronting healthcare professi...
Update from ESMO 2024: Immunotherapy (IO) for HCC
Просмотров 24 тыс.Месяц назад
In this video update, Dr Richard S. Finn shares his perspective on the latest hepatocellular carcinoma (HCC) data on immunotherapy (IO) and IO-based treatments to emerge from ESMO 2024. Dr Finn reviews data from the following clinical trials: - HIMALAYA - CheckMate 9DW - LEAP-012 - IMbrave050 Download the accompanying slides from the COR2ED website: cor2ed.com/n-connect/programmes/esmo-2024-lun...
Oncogene-addicted NSCLC update from WCLC and ESMO 2024
Просмотров 31 тыс.Месяц назад
In this video update, Dr Herbert H. Loong shares his perspective on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) to emerge from two important congresses, WCLC and ESMO 2024. Dr Loong reviews data from the following clinical trials (with corresponding video time stamps): 0:13 - TRUST-II 0:54 - LOXO-RAS-20001 1:47 - DESTINY-Lung03 3:02 - SOHO-01 & Beamion LUNG-1 4:07 - ...
ESMO 2024: Update on BRAF-altered lung cancer data
Просмотров 20 тыс.Месяц назад
Prof. Planchard and Dr Cappuzzo share their views on the latest data on BRAF-altered lung cancer presented at the ESMO 2024 congress. Watch and listen as the experts reveal what they consider to be the key clinical takeaways from the following NSCLC trials: - PHAROS - IFCT-1904 ENCO-BRAF - 1L IO vs BRAF and MEK inhibitors - MoST Professors Stintzing and Dummer discuss BRAF-altered colorectal an...
ESMO 2024: Lower GI cancer update
Просмотров 2,6 тыс.Месяц назад
Prof. Chiara Cremolini and Prof. Hans Prenen share their views on the practice-changing data on lower GI cancer presented at the ESMO 2024 congress. Watch and listen as the experts reveal what they consider to be the key clinical takeaways from the latest clinical trials on colorectal and rectal cancer. Dr. Sam Klempner and Dr. Lizzy Smyth discuss the upper GI cancer highlights from the meeting...
GU oncology update from ESMO 2024
Просмотров 13 тыс.Месяц назад
Dr Ray Manneh Kopp shares his views on the latest data on GU cancers presented at the ESMO 2024 congress. Watch as he reveals what he considers to be the key clinical takeaways from the following GU cancer trials: NIAGARA EORTC-GUCG 1333/PEACE-3 TiNivio-2 COR2ED brings together a selection of top experts across many tumour types, presenting their thoughts and insights on the most recent data to...
ESMO 2024: BRAF-altered colorectal and other cancers
Просмотров 30 тыс.Месяц назад
Prof. Sebastian Stintzing and Prof. Reinhard Dummer share their views on the latest data on BRAF-altered colorectal and other cancers presented at the ESMO 2024 congress. Watch the experts reveal what they consider to be the key clinical takeaways from the latest data presented on BRAF-altered colorectal cancer, brain cancer, melanoma and solid tumours. Prof. David Planchard and Dr Federico Cap...
Update from ESMO 24: Breast cancer
Просмотров 14 тыс.Месяц назад
Prof. François-Clément Bidard shares his views on the latest breast cancer data presented at the ESMO 2024 congress. Watch as he reveals what he considers to be the key the clinical takeaways from the latest results shared from the following breast cancer trials: KEYNOTE-522 DESTINYBreast-12 NATALEE COR2ED brings together a selection of top experts across many tumour types, presenting their tho...
ESMO 2024: Upper GI cancer update
Просмотров 2,5 тыс.Месяц назад
Dr Lizzy Smyth and Dr Sam Klempner share their views on the practice-changing data on upper GI cancer presented at the ESMO 2024 congress. Watch and listen as the experts reveal what they consider to be the key clinical takeaways from the latest clinical trials on gastric and gastroesophageal cancer. Prof. Hans Prenen and Prof. Chiara Cremolini discuss the lower GI cancer highlights from the me...
Neuroendocrine tumours (NETs) - Shared decision-making. Episode 1: Patient journey
Просмотров 22 тыс.2 месяца назад
Neuroendocrine tumours (NETs) - Shared decision-making. Episode 1: Patient journey
Highlights: NET Shared decision making - optimising physician and patient consultations
Просмотров 1132 месяца назад
Highlights: NET Shared decision making - optimising physician and patient consultations
Neuroendocrine tumours (NETs)-Shared decision-making. Episode 2: Individualising treatment decisions
Просмотров 22 тыс.2 месяца назад
Neuroendocrine tumours (NETs)-Shared decision-making. Episode 2: Individualising treatment decisions
Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMM
Просмотров 1392 месяца назад
Relapsed/refractory multiple myeloma (RRMM): Best practices in treating early RRMM
Relapsed/refractory multiple myeloma (RRMM): The relevance of adding a new MoA
Просмотров 1,3 тыс.2 месяца назад
Relapsed/refractory multiple myeloma (RRMM): The relevance of adding a new MoA
Multiple Myeloma: Unmet medical needs in early relapse
Просмотров 2,8 тыс.2 месяца назад
Multiple Myeloma: Unmet medical needs in early relapse
Update from ASCO GI 2023 Upper GI cancer highlights podcast (SHORT)
Просмотров 993 месяца назад
Update from ASCO GI 2023 Upper GI cancer highlights podcast (SHORT)
Tools for optimising treatment & management of advanced NETs
Просмотров 28 тыс.3 месяца назад
Tools for optimising treatment & management of advanced NETs
The evolving role of liquid biopsy
Просмотров 58 тыс.4 месяца назад
The evolving role of liquid biopsy
Highlights: Precision oncology in practice- testing through to treatment in lung and prostate cancer
Просмотров 864 месяца назад
Highlights: Precision oncology in practice- testing through to treatment in lung and prostate cancer
Advanced renal cell carcinoma: Managing long term durable response
Просмотров 20 тыс.4 месяца назад
Advanced renal cell carcinoma: Managing long term durable response
Advanced HCC: Treatment options for patients ineligible for IO - patient case video
Просмотров 744 месяца назад
Advanced HCC: Treatment options for patients ineligible for IO - patient case video
Highlights- Optimising the management of multiple myeloma in the early relapsed refractory setting
Просмотров 1574 месяца назад
Highlights- Optimising the management of multiple myeloma in the early relapsed refractory setting
Optimising the management of multiple myeloma in the early relapsed/refractory setting
Просмотров 29 тыс.5 месяцев назад
Optimising the management of multiple myeloma in the early relapsed/refractory setting
😊😊
8
Good
Nice❤❤❤
Pl Pp LpPlPp
😊😅😮😮😮❤❤❤❤❤
Shut up 🤫
عندي مرض مناعي
❤😂🎉
Good
😢😮
Hola
Thank you for all you do.
Women. Women getting IUD.
"Fear of pain amongst people getting IUDs" is because doctors often dismiss and downplay their pain giving just some ibuprofen cause they dont take their pain seriously
I'm sure the men getting their IUD put in have their pain taken seriously
Why did you say "people" considering an IUD? Last I checked, men don't have the parts needed to need an IUD. So, it should have been women considering an IUD.
Last time I checked, women were still people. Also, trans men exist.
@@Pfluftl4326 screw that. Stop erasing women from language. I'm tired of this misogyny.
@@brokenandcrakeddon't pretend to not know and wonder what they meant when they said "people" like you don't know they're referring to trans people who have a uterus. Womp womp "trans men and intersex people exist so I'm going to be transphobic and get offended like the snowflake I am" lmao cope
There's no such things as trans men getting IUD. And they're not women.
@@brokenandcrakedTrans-inclusion is NOT erasure of women. I'm a cis woman and I am proud to support trans women.
>>Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity’s 67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical response to treatment and an indicator of the recurrence of disease for prostate cancer.<<
It took me 9 cycles to completely eradicate my metastatic lesions in my bones. My first scans were mixed due to being off my soc x 4 months before starting Elacestrant. I scan every 90 days. And made many improvements every scan. It’s been my miracle- after 6.5 yrs on a soc prior.
The slides are illegible
Hello @jstanbury61, slides are available for download on our website and you can find them here: cor2ed.com/gu-connect/programmes/expert-knowledge-share-incorporating-parp-inhibitors-into-prostate-cancer-clinical-practice/ Thanks!
😊
Hello
VON WİLLİBRAND HEMOFİLİ A FACTOR 8 Type 2 b 😢😢😢😢😢😢😢😢
I’m so much excited about how dr OARE on RUclips channel was able to shrunk and cure my multiple fibroid and heavy period, thank you 🙏 very much xx dr OARE and you too can also visit him on RUclips channel for any compliant.